NDAINTRAVENOUSSOLUTION
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBY-FILL (Rubidium Rb 82) is an intravenous diagnostic radiopharmaceutical used for myocardial perfusion imaging in patients with suspected or known coronary artery disease. It is a positron-emitting isotope administered as a solution for cardiac PET imaging to assess regional myocardial blood flow and perfusion defects.
Peak
Peak lifecycle positioning indicates stable commercial operations with established market presence and mature team infrastructure at Jubilant Therapeutics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RUBY-FILL is a specialized diagnostic agent with niche career opportunities focused on hospital relationships, physician engagement, and reimbursement strategy rather than broad pharmaceutical sales. Roles emphasize technical knowledge of cardiac imaging protocols and healthcare economics.
Diagnostic Product ManagerMedical Science Liaison
Worked on RUBY-FILL at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.